论文部分内容阅读
甲硫咪唑酮(Enoximone,MDL17043,以下简称En)是一种口服和静注均有效、兼有正性肌力和血管扩张作用的新型人工合成咪唑类药物,从八十年代开始对其进行的大量动物实验和临床研究结果表明,它对严重的充血性心力衰竭(CHF)有良好的血流动力学效应和临床疗效,副作用小,基本无毒性,已引起了临床医师和药师广泛的注意。药理作用一、作用机理:En是一种结构独特,不同于儿茶酚胺类、二吡啶类或强心甙类的新型咪唑类药物,它兼有正性肌力和血管扩张作用,比目前所有的强心甙具有更大的治疗指数和更小的毒副作用,并且口服和静注均有效。经体
Enoximone (MDL17043, hereinafter referred to as En) is a new type of synthetic imidazole that is effective both orally and intravenously and has both inotropic and vasodilating effects. Since the 1980’s, Enoximone (MDL17043, hereinafter referred to as En) A large number of animal experiments and clinical studies have shown that it has a good hemodynamic response to severe congestive heart failure (CHF) and clinical efficacy, with little side effects, basically non-toxic, has attracted widespread attention of clinicians and pharmacists. Pharmacological effects First, the mechanism of action: En is a unique structure, different from catecholamines, dipyridyl or cardiac glycosides of new imidazole drugs, which both positive inotropic and vasodilator effect than all the current strong The glycosides have a larger therapeutic index and less toxic side effects, and are effective both orally and intravenously. After the body